AIM ImmunoTech Inc.
Market Cap
12M
Short interest (May 15)
1.7%
Net Short (Jun 03 ): 3.4%
Borrow Fee
207.31%
↑ 49.0%
Available Shares
20K
↓ 50.1%
Price Chart
Company Overview
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.